Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of S095035 (MAT2A inhibitor) in MTAP-deleted advanced solid tumors
jRCT2031240560Phase 2Active, not recruiting
- Sponsor
- Servier
- Start
- Apr 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of s095035 in Nonhematologic neoplasms and glioblastoma (GBM) (2 arms), sponsored by Servier. Primary endpoints: Dose-limiting toxicities (DLTs) during Cycle 1 (dose escalation part), Overall safety and tolerability (dose escalation part) and 1 more. Started Apr 2025; status: active, not recruiting.
02
Drugs
s095035
03
Conditions
Nonhematologic neoplasmsglioblastoma (GBM)
Beyond the preview
Go deeper on jRCT2031240560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240560.